Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 11/20 | 0.75 |
| ▸ | CA1 | P00915 | 7/20 | 0.75 |
| ▸ | CA12 | O43570 | 6/20 | 0.75 |
| ▸ | CA2 | P00918 | 4/20 | 0.58 |
| ▸ | ESR1 | P03372 | 2/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383638 | 0.93 | CA9 (0.71) | CA9CA1CA12CA2ESR1 | |
| SCHEMBL5647824 | 0.83 | ESR1 (0.70) | CA9CA1CA12CA2ESR1 | |
| SCHEMBL5198978 | 0.79 | ALDH1A1 (0.64) | CA9CA1CA12CA2ESR1 | |
| SCHEMBL27475071 | 0.79 | CA9 (0.62) | CA9CA1CA12CA2ESR1 | |
| SCHEMBL2357830 | 0.79 | CA9 (0.61) | CA9CA1CA12CA2ESR1 | |
| SCHEMBL29710383 | 0.79 | CA9 (0.66) | CA9CA1CA12CA2ESR1 | |
| SCHEMBL9633890 | 0.79 | CA9 (0.66) | CA9CA1CA12CA2ESR1 | |
| SCHEMBL374398 | 0.78 | CA9 (0.60) | CA9CA1CA12CA2ESR1 | |
| SCHEMBL3626463 | 0.76 | CA9 (0.58) | CA9CA1CA12CA2ESR1 | |
| SCHEMBL7921955 | 0.76 | CA9 (0.57) | CA9CA1CA12CA2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576119-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | claimed |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | claimed |
| US-7202264-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | claimed |
| EP-1670810-A2 | GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLI CSUGAR MOIETIES AT THE TERMINI | Isis Pharmaceuticals, Inc. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050208588-A1 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | claimed |
| US-20050059066-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | IONIS PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | claimed |
| WO-2005023825-A2 | GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLIC SUGAR MOIETIES AT THE TERMINI | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| US-20050053981-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | ISIS PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | claimed |
| US-20040242897-A1 | Universal support media for synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004011474-A1 | UNIVERSAL SUPPORT MEDIA FOR SYNTHESIS OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2004-02-05 | — | — | WO | claimed |
| US-6124484-A | Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-26 | — | — | US | claimed |
| US-5721350-A | Deuterated nucleosides | CHATTOPADHYAYA JYOTI (SE) | 1998-02-24 | — | — | US | claimed |
| JP-H09510206-A | — | — | 1997-10-14 | — | — | JP | claimed |
| US-5623068-A | Synthesis of DNA using substituted phenylacetyl-protected nucleotides | BECKMAN INSTRUMENTS, INC. (US) | 1997-04-22 | — | — | US | claimed |
| EP-0749436-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1996-12-27 | — | — | EP | claimed |
| US-5574146-A | Oligonucleotide synthesis with substituted aryl carboxylic acids as activators | BECKMAN INSTRUMENTS, INC. (US) | 1996-11-12 | — | — | US | claimed |
| EP-0725787-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-08-14 | — | — | EP | claimed |
| WO-1996006853-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-03-07 | — | — | WO | claimed |
| WO-1995024413-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1995-09-14 | — | — | WO | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | CA9 3036/4885CA1 2308/4885CA12 2383/4885 |
| US-20050059066-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | OGG1, UNG, PCNA | CA9 4009/4885CA1 4569/4885CA12 4189/4885 |
| US-20050053981-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | OGG1, UNG, PCNA | CA9 4009/4885CA1 4569/4885CA12 4189/4885 |
| US-20050208588-A1 | Supports for oligomer synthesis | ILK, NOP2, PFAS | CA9 3036/4885CA1 2308/4885CA12 2383/4885 |
| US-20040242897-A1 | Universal support media for synthesis of oligomeric compounds | NEFM, POLRMT, POLM | CA9 4492/4885CA1 3113/4885CA12 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.